Epithelial Cytokines and Chronic Airway Diseases

Target Audience

The educational design of this activity addresses the needs of clinical immunologist/allergist and ear, nose, and throat (ENT) specialists, as well as pulmonologists, who manage patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Program Overview

Chronic inflammatory diseases of the upper and lower airways, especially CRSwNP, have been tied to significant risks and burdens for affected patients. Although biologic therapies that target overactive cytokine signaling are available, newer therapies are emerging, with targets upstream in the pathogenic cascade to improve efficacy across both type 2 (T2)-high and T2-low profiles. Join us for this engaging Expert Roundtable where faculty will present a 3D animation of pathophysiologic processes in the upper airway epithelium and you can gain multidisciplinary insights on burdens and management challenges associated with CSRwNP and learn about current and emerging treatment options.

Educational Objectives

After completing this activity, the participant should be better able to:

1. Describe the contributions of epithelial cytokine signaling to the pathogenesis of CRSwNP
2. Evaluate patients with CRSwNP for symptom burden, disease phenotype, and effects on health-related quality of life
3. Discuss the clinical profiles of current and emerging biologic therapies, including anti–thymic stromal lymphopoietin agents, for patients with CRSwNP
4. Tailor CRSwNP treatment regimens based on patient symptoms, endotype, treatment goals, and comorbidities

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Continuing Medical Education

Integritas designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pretest, posttest, and program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Kathleen M. Buchheit, MD: Consulting Fees: AstraZeneca plc, Eli Lilly and Company, GSK plc, Regeneron Pharmaceuticals, Inc., Sanofi; Contracted Research: Regeneron Pharmaceuticals, Inc.

Joseph K. Han, MD: Consulting Fees: AstraZeneca plc, GSK plc, Regeneron Pharmaceuticals, Inc., Sanofi

Flavia Hoyte, MD: Consulting Fees: AstraZeneca plc, Genentech, GSK plc, Sanofi, Teva Pharmaceutical Industries Ltd.; Fees for Non-CE Services Received Directly From an Ineligible Entity or Their Agents: AstraZeneca plc; Stock Shareholder: Amgen

The Integritas planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.